To assess the effects of aging on glucose-mediated glucose disposal and glucose transport, glucose disposal rates were measured in 10 nonelderly (32±4 yr) and 11 elderly (64±4 yr) subjects at five different plasma glucose concentrations. Glucose disposal was decreased by 30-35% in the elderly at each level ofglycemia (100-350 mg/dl) in the presence of similar levels of hyperinsulinemia (-100 MU/ml), and the 50% effective concentration (EC50) was similar in both the nonelderly (100±9) and elderly (103±5 mg/dl). The Michaelis constant (K.) of3-0-methyl glucose transport in adipocytes was unchanged with aging (3.8±0.5 vs. 3.2±0.2 mM) while the maximum velocity of insulin stimulated transport was reduced by 34% in the elderly (8.3±13 vs. 12.6±1.5 pmol/5 X 104 cells per s, P < 0.05). The insulin resistance of aging is therefore due to a reduction in the capacity of the glucose uptake system, while the affinity of glucose utilization (EC5o and K.,) is unchaned. This supports the hypothesis that a reduction in the number of glucose transport and metabolic units occurs with aging, but that each unit functions normally.
Introduction
Glucose intolerance is a well recognized characteristic ofhuman aging (1) . This glucose intolerance is generally accompanied by hyperinsulinemia, indicating an insulin-resistant state. Indeed, evidence in favor of insulin resistance was presented some 40 years ago by Himsworth and Kerr, who demonstrated a decrease in insulin sensitivity with aging using an oral glucose tolerance test with a simultaneous intravenous insulin injection (2) . These conclusions have been substantiated over the years, primarily with the advent of the glucose clamp technique, which has enabled us to not only establish the existence of insulin resistance with aging, but also to quantitate the severity of the resistant state and to gain insights as to its mechanisms (3) (4) (5) (6) . Recent in vivo data using the euglycemic glucose clamp technique to construct insulin dose-response curves for glucose disposal have indicated that insulin resistance in aging manifests itselfas a rightward shift in the insulin dose-response curve with maximal responsiveness ranging from normal to markedly decreased, depending on the degree of glucose intolerance present in the elderly (4, 5) . When insulin binding to either adipocytes or monocytes has been simultaneously measured in these studies, no changes could be demonstrated in the aged. Since insulin resistance exists in the face of normal insulin binding, the probable locus of the insulin resistance must reside at a postbinding step. We and others have demonstrated a decrease in glucose transport activity in adipocytes from elderly subjects (7, 8) that is consistent with this formulation. Furthermore, more distal defects in intracellular metabolism involving decreased maximal glucose oxidation have also recently been identified with aging (9) . All these studies, therefore, point to a postbinding defect in insulin action that occurs with aging. However, they do not distinguish between the effects ofinsulin on the processes ofglucose metabolism and a defect in the glucose metabolism processes themselves.
In an effort to further elucidate the mechanisms of insulin resistance in aging, we have utilized the glucose clamp technique to study insulin-stimulated glucose disposal rates over a wide range ofglucose concentrations in younger and older individuals. The purpose of the study was to examine the in vivo kinetic characteristics of glucose utilization by measuring the effects of glucose in stimulating its own disposal and thus to determine whether there existed alterations in the efficiency or capacity of glucose disposal with aging. In addition, we have examined the kinetic characteristics of the glucose transport system in adipocytes from the same population to determine the maximum velocity (Vma.) and the Michaelis constant (K.) ofglucose transport in young and old and to provide in vivo and in vitro correlates.
Methods
Materials [3-3H] glucose was purchased from New England Nuclear (Boston, MA).
Bovine serum albumin (fraction V) was obtained from Boehringer Mannheim Biochemicals (Indianapolis, IN). Collagenase was purchased from Cappel/Worthington Life Science (Malvern, PA). Cyclic somatostatin (SRIF)' was purchased from Bachem Corp. (Torrance, CA).
Subjects
The study group included a total of 21 nonobese healthy volunteers, divided into two groups on the basis of age. The nonelderly group consisted of 10 men aged 26-40 yr (mean±SD, 32±4 yr) and the elderly group consisted of 10 men and I woman aged 60-70 yr (mean±SD, 64±4 yr). All subjects were within 20% of ideal body weight, based on the Metropolitan Life Insurance Tables. They were in good general health and had no evidence of renal, hepatic, or cardiac dysfunction. None of the subjects was taking any medication during the study, with the exception of iron supplementation. After informed consent was obtained, subjects were admitted to the Special Diagnostic and Treatment Unit of the San Diego Veterans Administration Medical Center. Daily carbohydrate intake as determined by dietician-obtained histories was 150 g in both nonelderly and elderly subjects in the week before the studies. Subjects were weighed daily and calories adjusted to maintain initial weight throughout the study. The diet contained 45% carbohydrate, 35% fat, and 20% protein. The clinical and metabolic characteristics of the subjects are summarized in Table I. An oral glucose tolerance test (75 g) was performed before participation of each subject in the experimental protocol. Six of the elderly group and one of the nonelderly group had 2-h plasma glucose values greater than 140 mg/dl. Three of the six elderly subjects had impaired glucose tolerance while the other three and the one nonelderly individual had nondiagnostic glucose tolerance tests as defined by the National Diabetes Data Group (10). As a whole, the elderly group was sgnificantly more glucose intolerant than the nonelderly group as indicated by the 2-h glucose values. [3-3H] glucose during the hyperglycemic studies, since under the conditions ofour protocol, i.e., hyperinsulinemia, hyperglycemia, and glucagon deficiency due to the infusion ofSRIF, hepatic glucose output is completely suppressed.
In fact, even during the studies done at the lowest plasma glucose concentration of 100 and 150 mg/dl, hepatic glucose output was completely suppressed in both age groups.
After the initiation of the glucose and insulin infusions, the desired level ofglycemia was maintained for at least 180 min, or until the glucose infusion rate had not changed by more than ±10% for 60 min. The mean length for each study was 194 min with a range of 180-260 min. There was no difference between the two groups in the length of study (194±5 min vs. 194±2 min in the nonelderly and elderly, respectively). The glucose disposal rates for the last three 20-min intervals of each study were measured and used as the datum point for that particular study. 
Results
Glucose clamp studies: plasma glucose, insulin, and C peptide (Table II) : The goal glucose levels were attained in both groups with a coefficient of variation of <5% for each of the studies performed. Steady state serum insulin levels were similar (100 MU/ml) in both the elderly and nonelderly group at each level of glycemia, with the sole exception of the elderly group studied at a plasma glucose concentration of 350 mg/dl where the serum insulin level was somewhat higher (124±6 ,U/ml) compared with the nonelderly group (109±6 ,uU/ml, P < 0.05). Despite the increasing plasma glucose levels attained during the clamp studies, endogenous insulin secretion remained suppressed due to the SRIF infusion. Even at a glucose concentration of 350 mg/dl, C peptide was suppressed by 40±1 1% in the nonelderly and 41±9% in the elderly group (Table II) . Absolute basal C peptide values were similar in both groups as well (0.35±.04 vs. 0.38±.03 pmol/ml in the nonelderly and elderly, respectively) and no difference was observed in the ability of SRIF to inhibit endogenous insulin release in the two age groups. In both the elderly and nonelderly, however, SRIF resulted in a greater suppression of C peptide at lower glucose levels of 100 and 150 mg/dl compared with the hyperglycemic levels of 250 and 350 mg/dl (Table II) . Table III ). This indicates that the insulin resistance of aging is expressed equally at all glucose levels and that it is the maximal capacity for glucose metabolism which is impaired. The decrease in glucose uptake in the elderly was similarly apparent when the data were analyzed on a per kilogram LBM basis ( Fig. 1 B, Table III, P < 0.05, F = 6.75, ANOVA). Hepatic glucose output was completely and equally suppressed by 100% in both age groups during the studies done at plasma glucose concentrations of 100 and 150 mg/dl. Because of this complete suppression at lower glucose concentrations, [3- 3H]glucose was not infused during studies done at higher plasma glucose levels of 200, 250, and 350 mg/dl.
Glucose utilization increased significantly (P < 0.05) in both the nonelderly and elderly subjects when the plasma glucose concentration was increased from 100 to 250 mg/dl during the 40 mU/M2 per min insulin infusions. However, increasing the glucose concentration from 250 to 350 mg/dl resulted in no significant increase in glucose disposal rates in both groups (15.2±1.6 vs. 16.4±1.5 mg/kg per min in the nonelderly group and 10.9±1.0 vs. 1 1.3±0.9 mglkg per min in the elderly group).
This indicates that glucose utilization was almost totally saturated at a glucose level of 250 mg/dl during physiological hyperinsulinemia.
In order to more closely examine the ability of glucose to increase total glucose disposal, and to determine if aging resulted in an impaired ability of an increasing glucose concentration to increase glucose utilization, the glucose disposal rates were analyzed as a percentage of the maximal glucose disposal and the change in the percent increase in glucose disposal per change in plasma glucose (slope) (19) was examined in both groups (Fig.  2) . This relationship was evaluated over the glucose concentrations where glucose uptake increased in a fairly linear fashion, i.e., from 100 to 250 mg/dl. This was confirmed by least squares linear regression analysis and indicated that the slope did not differ significantly between the nonelderly (r = 0.91±0.03, slope = 0.25±0.03) and elderly groups (r = 0.90±0.04, slope = 0.26±0.03, P = NS). The similar effectiveness of glucose in increasing glucose uptake in both the nonelderly and elderly subjects is further illustrated by the plasma glucose concentration at which half the maximal glucose disposal rate was observed (EC50). This was determined for each individual based on a plot ofthe percent of maximal glucose disposal versus plasma glucose concentrations. These values (Fig. 2) were virtually identical in the two groups, 100±9 mg/dl in the nonelderly subjects and 103±5 mg/dl in the elderly subjects (P = NS). As predicted by the similar EC50 values in the two groups, there was no significant relationship observed between the EC50 and the 2-h plasma glucose value during the oral glucose tolerance test (r = 0.18, nonelderly; r = -0.27, elderly; P = NS) or between the slope as derived in Fig. 2 and the 2-h glucose value (r = -0.14, nonelderly; r = 0.21, elderly; P = NS). The glucose disposal curves were also analyzed using the assumption that in vivo glucose uptake follows Michaelis-Menten kinetics as suggested by Gottesman et al. (20) . Eadie-Hofstee plots generated straight lines with similar Km values of 296±54 vs. 296±25 mg/dl but with a 26% reduction in V in the elderly (21.9±2.1 vs. 29.4±3.8 mg/kg per min, P < 0.05).
Adipocyte glucose transport. (Fig. 3 ) Basal rates of glucose transport were similar in the nonelderly and elderly subjects at all glucose concentrations ranging from 0.1 to 50 mM. Insulin, however, resulted in a greater stimulation of glucose transport in the nonelderly compared with the elderly (P < 0.05, F = 5.02, ANOVA). Since glucose transport follows Michaelis-Menton kinetics, the data were analyzed by Eadie-Hofstee plots in order to determine the Km and V. ofglucose transport in each group (Fig. 4) . In the basal state, the Km and V. of glucose transport were not significantly different in the nonelderly (Km = 3.1±0. (Table   IV ). In addition, the effect of insulin to stimulate glucose transport was decreased in the fat cells from the elderly with a 20% reduction in the fold insulin stimulation (2.5-fold increase in the nonelderly compared with a twofold increase in the elderly). Since cell size was somewhat larger in the elderly (Table I) , this reduction in the V., ofglucose transport is even more apparent when the data are expressed on a per cell surface area basis, rather than per cell number. In the basal state, the V. ofglucose transport was decreased by 28% in the elderly group, although this difference did not quite achieve statistical significance (6.2 vs. 8.6 pmol/2 X I09 u2 per s, P = 0.07 in the elderly and nonelderly, respectively). In the presence of insulin, however a 40% reduction in the V. of glucose transport was observed in the elderly (13.2±2.5 vs. 21.2±2.6 pmol/2 X 109 As2 per s, P < 0.05 in the elderly and nonelderly, respectively).
Discussion
We have previously found that aging is associated with insulin resistance using euglycemic clamps across the dose-response curve for insulin for a single glucose concentration (4) . Overall glucose disposal encompasses the processes ofglucose transport and metabolism and the effects of insulin on these processes. The presence of insulin resistance at various insulin concentrations at a single glucose concentration does not, however, distinguish between the effects of insulin on the glucose metabolism processes and a defect in the glucose metabolism processes themselves. One way to approach this problem is to study insulin stimulation ofglucose disposal across a range of plasma glucose concentrations at a fixed insulin concentration. Increasing the plasma glucose concentration leads to increased rates ofglucose disposal due to the mass action effectiveness of glucose in increasing flux through the glucose transport system. Therefore, by studying insulin-stimulated glucose disposal across a range of glucose concentrations, one can distinguish between abnormalities of the glucose transport/glucose utilization system per se and insulin action on this system.
The results of our study indicate that the affinity of glucose utilization, as measured by the percent increment in glucose disposal rate per increment in plasma glucose concentration (slope), is the same in both age groups, implying that the similar reduction in glucose disposal observed in the elderly at all plasma glucose concentrations is not due to an impaired affinity of the glucose transport/metabolism units for glucose, but rather due to a reduction in the number offunctioning units available. This 8.3±1.3 P < 0.05 conclusion is supported by the in vivo data, which demonstrate a 30-35% decrease in glucose disposal rates in the elderly at all levels of glycemia, ranging from 100-350 mg/dl. However, despite the presence of insulin resistance, the incremental change in the percent of maximal glucose disposal rate per incremental change in glucose concentration, i.e., the slope, (Fig. 2) was similar in both age groups, as was the EC50, indicating that the affinity of the glucose uptake system for glucose is unaltered with aging. These in vivo findings are supported by the in vitro data, which indicate that the affinity ofglucose transport as measured by the Km is equal in both age groups. Since the functional integrity of the glucose transport system as measured by its Km and the functional integrity of the glucose utilization system as measured by incremental glucose uptake is similar in both age groups, it follows that the affinity of glucose transport for total body glucose utilization must be normal.
Our results further indicate that although the affinity of in vivo glucose utilization is normal with age, there is a reduction in the maximal capacity of glucose utilization as demonstrated by the 30-35% reduction in glucose disposal rates at all glucose concentrations studied. This reduction in maximal capacity indicates that a decrease in the number of glucose transport/metabolic units exists. Once again, the in vitro data support this conclusion, since the maximal capacity of glucose transport, as reflected in the Vm.., was reduced by 34% in the elderly group. Since insulin's ability to increase Vm. has been shown to be due to translocation of glucose transporters from low density intracellular microsomes to the plasma membrane (21, 22) , a decrease in Vm.. could be due to either a smaller absolute number of transporters or to decreased translocation or availability of transporters, either ofwhich results in a decreased in vivo glucose disposal at all glucose concentrations.
Chen and her colleagues (23) recently evaluated the mechanisms of age-related glucose intolerance using the minimal model approach. They also showed that older subjects were insulin-resistant but that so-called glucose effectiveness, i.e., the increase in fractional disappearance ofglucose per unit increase in glucose, was unchanged with aging. Our results are in agreement with these data, and indicate that the effect of increasing glucose concentrations to increase glucose uptake is not decreased in the glucose-intolerant aged population both at basal serum insulin levels (23) and at serum insulin levels of about 100 MU/ml. Documenting the effects of aging per se to influence insulin action and glucose metabolism is fraught with the difficulties of separating out age-related variables such as obesity, physical activity, and caloric intake, each known to independently alter insulin action. It is unlikely, however, that the differences between the nonelderly subjects and elderly subjects could be entirely accounted for by these factors. Firstly, LBM was not significantly different between the two groups, and when the data were analyzed on a per kilogram LBM basis, similar differences in glucose disposal rates between the two age groups could be seen. Secondly, fat cell size, another independent marker ofobesity, was not significantly different between the nonelderly and elderly groups and, therefore, the differences in the glucose transport data could not be solely attributed to increased adiposity in the elderly. Thirdly, within age groups, and considering all glucose infusion levels, there were no statistically significant relationships between steady state glucose disposal rates and percent body fat (nonelderly, r = -0.29, P = NS; elderly, r = +0.24. P = NS). Although no measurements ofthe degree of physical conditioning of the subjects were made in our study, all subjects selected were fully active and leading nonsedentary lifestyles, and none were involved in any vigorous exercise program that may have unduly affected our results. Although dietary carbohydrate intake is often reduced with aging and could result in impairment in measurements of insulin action, it is unlikely to have accounted for any significant differences in our study, since all subjects were maintained on at least 150 g carbohydrate in the week before studies and on a weight-maintenance isocaloric diet during the study.
All the glucose clamp studies were done with insulin infusion rates of 40 mU/M2 per min and in the presence of SRIF. Even with steady state plasma glucose levels of 350 mg/dl, SRIF was still effective in suppressing endogenous insulin release as assessed by serum C peptide concentrations. The inhibition of insulin secretion was 40% compared with 92% at steady state plasma glucose levels of 150 mg/dl, but importantly, no breakthrough of endogenous insulin secretion occurred under these hyperglycemic conditions. Serum insulin levels were therefore comparable in both age groups at all glucose concentrations with the exception of a small 14% increased steady state insulin concentration in the elderly group studied at a plasma glucose concentration of 350 mg/dl. This did not alter the results ofthe studies, since glucose disposal rates were still decreased by 30-35% in the elderly at all plasma glucose concentrations, including the studies done at 350 mg/dl where the serum insulin levels were, in fact, higher.
Each of the clamp studies was done on a separate day and in order to compare results both between and within groups it was essential that serum insulin levels be closely matched. 40 mU/M2 per min insulin infusions were thus chosen, since we and others (3) (4) (5) have previously demonstrated that serum insulin concentrations of 100 ,U/ml were attained in both younger and older subjects. A lower insulin infusion rate would have resulted in considerably higher serum insulin levels in the elderly because ofthe decrease in the metabolic clearance rate ofinsulin, which is more evident at lower insulin concentrations (24) and has been shown in prior studies (24) (25) (26) .
Recently, it has been suggested that SRIF may have an independent effect in increasing peripheral glucose utilization (27) .
These results were demonstrated in dogs, and although there has been no confirmation of this observation in humans, it is unlikely that this would have significantly influenced our data.
We have used a 600 ,g/h dose of SRIF to ensure inhibition of insulin secretion at the higher plasma glucose levels. Even this dose, however, is only 15-20% (on a per kilogram basis) of the dose used in dog studies, which demonstrated the independent glucose lowering effect of SRIF (27) . In addition, we used the same dose of SRIF for all studies regardless of the steady state plasma glucose and, therefore, valid comparisons ofglucose disposal rates can be made within and between the two age groups. Finally, the magnitude of the SRIF effect would likely be quite small in relation to the total glucose disposal rates measured at hyperinsulinemia and hyperglycemia. The previously reported SRIF effect was demonstrated during basal insulin replacement (27) . SRIF inhibits not only insulin release but also growth hormone secretion and glucagon release. The deficiencies of both these hormones would have very little impact on the results of our studies for the following reasons. Glucagon has previously been shown to have no effect on peripheral glucose uptake (28) and prolonged infusions (longer than 6 h) of growth hormone are necessary to demonstrate an effect on glucose uptake (29). The duration of our infusions was considerably less (3-4 h) and therefore it is unlikely that we were overestimating the glucose disposal rates as a result of growth hormone deficiency.
A finding of considerable interest in our study was the abrupt saturation of glucose uptake that occurred in both age groups between glucose concentrations of 250 and 350 mg/dl. Studies done at plasma glucose concentrations of 350 mg/dl resulted in an insignificant 3.7% increase in glucose disposal rate compared with studies done at glucose levels of 250 mg/dl in both age groups. The plateauing of glucose uptake that occurs at these high plasma glucose levels could be due either to saturation of glucose transport or to the emergence ofa more distal postglucose transport step as the rate-limiting process for overall metabolism. If the rate-limiting step for overall glucose utilization resides at an intracellular step when the glucose concentration is raised from 250 to 350 mg/dl, then this would indicate that with aging the decrease in the V/m, of glucose transport accounts for the decrease in glucose disposal at plasma glucose concentrations between 100 and 250 mg/dl, but that further intracellular defects in glucose metabolism also exist which impair overall glucose utilization when the plasma glucose level is increased above 250 mg/dl. This conclusion is based on the fact that at a plasma glucose level of 350 mg/dl overall glucose disposal rates were 31% lower in the elderly group. If intracellular glucose metabolism is rate-limiting at this rate of glucose flux, then the defect in aging must reside at an intracellular locus with a resultant decreased capacity of glucose metabolism. On the other hand, ifglucose transport is still rate-limiting at a glucose concentration of 350 mg/dl, then the plateauing of in vivo glucose uptake is consistent with saturation of the transport system. The decrease in glucose disposal at all glucose levels would then be due to a decrease in maximal capacity ofglucose transport and a normal affinity ofthe glucose transport system with aging. Further studies will be necessary to distinguish between these possibilities.
It has previously been suggested by Gottesman et al. that in vivo glucose uptake could be analyzed by Michaelis-Menten kinetics and that insulin increases the V.. of glucose uptake without a change in the Km (20) . Glucose uptake was measured at several insulin concentrations, but at a maximal glucose concentration of only 160 mg/dl, a point on the glucose dose-response curve where glucose uptake is still linear. Therefore, it was not demonstrated in that study that saturation of glucose uptake occurred, and one can question the assumption that Michaelis-Menten kinetics can be used to assess total body in vivo glucose uptake. Our data tend to cast doubt on the accuracy of this kind of analysis. Thus, when our data were analyzed using this assumption, Eadie-Hofstee plots generated straight lines with a Km of -300 mg/dl in both groups and a Vm.. of 29 and 21 mg/kg per min in the nonelderly and elderly groups, respectively. The Km values are clearly much higher than the actual EC50 values calculated from the glucose dose-response curves (-100 mg/dl in both age groups). Additionally, the calculated Vm. is a full twofold greater than the actual maximally measured glucose uptake at a plasma glucose concentration of 350 mg/dl. There are many reasons why whole-body glucose uptake may not follow Michaelis-Menten kinetics. Firstly, there is now recent evidence to indicate that not all tissues in the body respond equally to insulin in increasing glucose uptake (30, 31) . For example, the maximal responsiveness of rat diaphragn is fivefold greater than that of rat lung tissue (31) . Secondly, differences exist even in similar tissues, such that insulin-mediated glucose uptake in skeletal muscle consisting primarily of oxidative fibers is substantially different from glucose uptake in glycolytic muscle (32) . Therefore, differences in muscle composition between one individual and another may play a role in determining total-body glucose uptake and these different types of insulin-responsive tissue may also have different kinetics ofglucose uptake. Thirdly, glucose uptake is not a homogeneous process but consists of both insulin-mediated glucose uptake and noninsulin-mediated glucose uptake (NIMGU) (33). NIMGU largely involves central nervous system glucose metabolism, and it is likely that the kinetics of glucose uptake into the central nervous system differ substantially from that in peripheral tissues; this further weakens the analysis of whole-body glucose uptake by simple MichaelisMenten kinetics. Therefore, it appears that overall glucose disposal rates are composed of several different uptake rates in different tissues and on aggregate they do not conform to Michaelis-Menten kinetics. It is probable, though, that in each individual tissue one could use this analysis to define the glucose uptake characteristics.
It has previously been shown that glucose uptake is not independent of the plasma glucose concentration and that the metabolic clearance rate of glucose (MCR) decreases with increases in glucose concentrations (34-36). Our data are consistent with this view and indicate that even when glucose utilization is linear over a range ofglucose concentrations, the MCR is still falling. In the nonelderly group the MCR decreased by 26% with increasing glucose concentrations from 100 to 250 mg/dl, while it fell by a similar 24% in the elderly group. The reduction in MCR occurred in the presence of insulin levels of about 100 ,gU/ml, a level at which the effectiveness of increasing glucose concentration to decrease the MCR has been shown to be minimal (37) . Thus, even in the presence of hyperinsulinemia, it is clear that the saturation kinetics ofglucose uptake coupled with the smaller relative contribution of NIMGU to total glucose uptake result in a decreasing MCR of glucose with increasing glucose concentrations.
In conclusion, we have evaluated the effectiveness ofglucose in increasing glucose utilization in the presence of physiological hyperinsulinemia in a group ofyounger and older subjects. Glucose uptake is linear in both groups up to a plasma glucose of about 250 mg/dl; thereafter total glucose disposal is virtually completely saturated. Glucose increases glucose uptake to a similar degree in both age groups, but at a lower total glucose disposal rate in the elderly, indicating their insulin resistance.
The decrease in maximal glucose uptake with normal affinity ofglucose uptake that occurs with aging is reflected in a decreased V,,a. of glucose transport activity with a normal Km in the elderly group. These data are consistent with the possibility that a decrease in glucose transporter numbers or a lower rate of translocation of transporters, rather than an altered function of a glucose transporter unit, underlies the insulin resistance of aging. In addition, a decrease in the maximal capacity of intracellular glucose metabolism may also exist with aging. These data, when analyzed together with previous studies (4, 5, 9) indicate that there are two major components to the insulin resistance of aging. First, there is a decrease in the total capacity of glucose utilization, although each ofthe transport/metabolic units functions normally. Second, evidence exists that insulin action is abnormal in aging. The evidence for abnormal insulin action is that basal glucose transport is normal but that the effectiveness of insulin in stimulating transport (fold increase) is decreased.
In addition, the in vivo insulin dose-response curves are shifted right-ward in the face of normal insulin-binding, indicating a postbinding defect in the insulin action system.
